Prolonged systemic administration of the KMO inhibitor Ro 61–8048 reduced L‐DOPA–induced dyskinesias in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)–treated monkeys with overt symptoms of parkinsonism.206. Here, KMO is linked to Dyskinesia.